人自然杀伤性细胞NK92

细胞名称

人自然杀伤性细胞NK92

货物编码

BFN608006464

产品规格

T25培养瓶x1

1.5ml冻存管x2

细胞数量

1x10^6

1x10^6

保存温度

37℃

-198℃

运输方式

常温保温运输

干冰运输

安全等级

1

用途限制

仅供科研           3类

培养体系

The base medium for this cell line is Alpha Minimum Essential medium without ribonucleosides and deoxyribonucleosides but with 2 mM L-glutamine and 1.5 g/L sodium bicarbonate . To make the complete growth medium, add the following components to the base medium: 0.2 mM inositol; 0.1 mM 2-mercaptoethanol; 0.02 mM folic acid; 100-200 U/ml recombinant IL-2; adjust to a final concentration of 12.5% horse serum and 12.5% fetal bovine serum.

培养温度

37℃

二氧化碳浓度

5%

简介

人自然杀伤性细胞NK92是从一位患有急进性非霍奇金淋巴瘤的50岁白人男性外周血单核细胞衍生来的一株白细胞介素-2依赖型NK细胞株。NK-92MI是转染得到的源自NK-92的IL-2非依赖的NK细胞株，亲本细胞通过微粒体基因转化法用逆转录病毒MFG-hIL-2载体携带的人IL-2cDNA进行转化。可能由于载体整合到基因组DNA中，转化是稳定的。这株细胞对很多恶性细胞有细胞毒性；铬释放试验显示它能杀死K562和Daudi细胞。NK-92细胞有以下特征：CD2 +, CD7 +, CD11a +, CD28 + , CD45 +, CD54 +, CD56 +, CD1 -, CD3 -, CD4 -, CD5 -, CD8 -, CD10 -, CD14 -, CD16 -, CD19 -, CD20 -, CD23 -, CD34 -, HLA-DR -。另本库保藏有NK92MI细胞。二者均引种自ATCC。

补充

NK92细胞培养时，会有零星聚团现象，此时吹打散开即可。处于平台期的细胞，会有少量呈现略不规则的圆形，此为正常现象。血清建议使用BCK北美胎牛血清（货号BCK041）与BCK马血清（货号BCK045)。

注释

Part of: LL-100 blood cancer cell line panel.

Characteristics: Laboratory use as a standard cell line for antibody-dependent cell-mediated cytotoxicity (ADCC) testing. Also bBeing developed for cellular adoptive immunotherapy for cancers and viral infections.

Characteristics: IL2 dependent.

Characteristics: Does not express FCGR3A/CD16.

Doubling time: 35.6 +- 6.1 hours (PubMed=31126350); ~40-50 hours (DSMZ).

Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).

Omics: Deep exome analysis.

Omics: Deep RNAseq analysis.

Omics: Transcriptome analysis.

Miscellaneous: Neukoplast is used as a trademark to refer to NK-92 cells that are available for non-human research applications while aNK is used as a trademark to refer to cells from the cGMP-grade NK-92 cell-line that is in use for therapeutic human testing.

Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and noncommercial suppliers of NK-92 cells. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support.

Derived from sampling site: Peripheral blood.

STR信息

Amelogenin        X,Y

CSF1PO        11,12

D5S818        12,13

D7S820        10,11

D13S317        9,12

D16S539        11,12

TH01        6,9.3

TPOX        8

vWA        18 (ATCC)

16,18 (DSMZ)

参考文献

PubMed=25586472; DOI=10.1038/ncomms7025

Kucuk C., Jiang B., Hu X., Zhang W., Chan J.K.C., Xiao W., Lack N., Alkan C., Williams J.C., Avery K.N., Kavak P., Scuto A., Sen E., Gaulard P., Staudt L.M., Iqbal J., Zhang W., Cornish A., Gong Q., Yang Q., Sun H., d'Amore F., Leppa S., Liu W., Fu K., de Leval L., McKeithan T., Chan W.C.

Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells.

Nat. Commun. 6:6025-6025(2015)

PubMed=26559813; DOI=10.1007/s00262-015-1761-x

Suck G., Odendahl M., Nowakowska P., Seidl C., Wels W.S., Klingemann H.-G., Tonn T.

NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy.

Cancer Immunol. Immunother. 65:485-492(2016)

PubMed=31126350; DOI=10.1186/s40425-019-0612-2

Yang H.G., Kang M.C., Kim T.Y., Hwang I., Jin H.T., Sung Y.C., Eom K.-S., Kim S.W.

Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy.

J. Immunother. Cancer 7:138-138(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x

Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.

The LL-100 panel: 100 cell lines for blood cancer studies.

Sci. Rep. 9:8218-8218(2019)